Platform session

Evaluation of Ketamine to Reduce Semi-Acute Electrophysiological and Behavioral Compromise following Nerve Agent Exposure

 

Dr. Waylon Weber, Ph.D. Research Scientist at Lovelace biomedical, will explain how his company uses emka TECHNOLOGIES’s rodentPACK along with IOX2 and ecgAUTO software, to perform the evaluation of Ketamine to Reduce Semi-Acute Electrophysiological and Behavioral Compromise following Nerve Agent Exposure.

Platform Session Title: Chemical and Biological Weapons

Session Time: Tuesday March 14, 2017 – 9:30 AM – 12:15 PM

Presentation Time: 3/14/2017 9:50:00 AM

Abstract Title: Evaluation of Ketamine to Reduce Semi-Acute Electrophysiological and Behavioral Compromise following Nerve Agent Exposure

Abstract Number: 1625

Where? Baltimore Convention Center – Room 314
1 W Pratt St. Baltimore MD 21201

See the SOT website.

Other posts you may like

British Pharmacological Society’s annual meeting

December 11-13, 2017 London, UK Booth #18

American Epilepsy Society

December 01-05, 2017 Washington, DC, USA Booth #319

Society for Neuroscience’s Annual Meeting

November 11-15, 2017 Washington, DC, USA Booth #2002

American Heart Association

November 11-15, 2017 Anaheim, CA, USA Booth #1401